Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding ...

IGV-001 is an autologous cell immunotherapy with antisense oligonucleotide targeting IGF-1R. In the phase 1b study, IGV-001 ...

The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine. Epstein-Barr virus is correlated with several malignancies, making this ...

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in ...

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at ...

Lopez-Chavez discusses promising new avenues for SCLC treatment, including with an investigational GM1 antibody by Bristol ...

The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free ...

9MW2821 was granted an orphan drug designation from the FDA and is being evaluated for the potential treatment of esophageal ...

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient ...

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive ...

As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer treatment.